Firms

Laurion Capital Management

Laurion Capital Management is a New York investment firm founded in September 2005 by Ben Smith and Sheehan Maduraperuma, former JPMorgan equity derivatives and proprietary trading colleagues. It combines quantitative and qualitative research across asset classes. Zhe (Jerry) Zhou became a partner in 2017 and leads its biotechnology investment strategies, bringing a background in biological sciences, biochemistry and molecular pharmacology. Its verified investments include Recursion's AI-enabled drug discovery platform, Exscientia's AI drug design, Scipher Medicine's precision immunology, Synthego's genome-engineering tools, TRexBio's computational immunobiology and Compass Pathways' mental-health therapeutics. These investments establish relevance to AI, deep technology and neuroscience, alongside the firm's broader capital-markets activities. Its public leadership directory names three partners; it does not publish a complete employee roster or venture-style portfolio catalogue.

Founded: 2005
Type: Venture capital

Funds0

No funds on record yet.

Team

Operations and support

Ben SmithFounding Partner

Sheehan MaduraperumaFounding Partner

Zhe (Jerry) ZhouPartner

Investments

$125M2023-08-16	Compass Pathways	Laurion Capital Management
$85M2022-03-08	TRexBio	Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Alexandria Venture Investments, Polaris Partners, Laurion Capital Management
$110M2022-02-24	Scipher Medicine	Cowen Healthcare Investments, Khosla Ventures, Alumni Ventures, aMoon, Northpond Ventures, Hitachi Ventures, Samir Kaul, Laurion Capital Management, Optum Ventures, Neuberger Berman, Echo Health Ventures
$200M2022-02-17	Synthego	Laurion Capital Management
$239M2020-09-09	Recursion Pharmaceuticals	DCVC, Felicis, Lux Capital, Laurion Capital Management
$225M2021-04-27	Exscientia	Laurion Capital Management

Funds0

Team

Operations and support

Co-investing

Investments